Depomed (DEPO) Misses Q2 EPS by 1c, Trims FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
DepoMed Inc (DEPO) PT Lowered to $9 at Piper Jaffray
August 8, 2017 8:23 AM EDTPiper Jaffray lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $9.00 (from $10.00) while maintaining a Neutral rating following Q2 results and another downward guide.
"Notably, DEPO cut its 2017 revenue and EBITDA guidance ranges once again, driven in part by continued headwinds... More
